Featured News

The Celiac Disease Foundation today announces the departure of Chief Development Officer Deborah Ceizler, who has served in key roles for more than 18 years.

Congratulations to Celiac Disease Foundation research partner Takeda Pharmaceuticals and its Medical Director Dan Leffler on recent media attention for three potential celiac disease therapies.

During May, Celiac Disease Awareness Month, the Celiac Disease Foundation wants to take this opportunity to honor the advocacy efforts of our dedicated, inspiring celiac disease patient community.

DDW 2023 showcased some of the latest research and innovations in celiac disease. These included promising early results from four investigational medications currently being tested for the treatment of celiac disease, as well as CDF research conducted in partnership with Takeda and Adelphi Real World.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

The Celiac Disease Foundation is proud to announce the recipients of the 2023 Global Celiac Disease Research Prizes, recognizing outstanding achievements in advancing research and treatment for celiac disease on a global scale.

We are delighted to report at the beginning of this calendar year two significant milestones in our ongoing efforts to compel the federal government to treat celiac disease with the seriousness it deserves.  

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.

We are pleased to announce that CDF Board Member, Kristin Yarema, PhD, was honored as a 2022 Medical Marketing & Media Woman of Distinction.

The Celiac Disease Foundation is in discussion with a team at the University of Colorado, Denver to develop the first-ever, FDA-approved pediatric PRO (patient-reported outcome tool).